Swiss National Bank Glycomimetics Inc Transaction History

Swiss National Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 06, 2020	SELL	$4.03 - $6.5 $258,726 - $417,300	-64,200 Closed	0 $0
Q2 2019 Aug 02, 2019	BUY	$10.6 - $13.12 $13,780 - $17,056	1,300 Added 2.07%	64,200 $765,000
Q1 2019 May 10, 2019	BUY	$9.96 - $13.44 $19,920 - $26,880	2,000 Added 3.28%	62,900 $784,000
Q4 2018 Feb 13, 2019	BUY	$8.47 - $14.71 $14,399 - $25,007	1,700 Added 2.87%	60,900 $577,000
Q2 2018 Aug 09, 2018	BUY	$14.63 - $19.19 $866,096 - $1.14 Million	59,200 New	59,200 $955,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $20.4M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.